Are Metabolically Healthy Overweight and Obesity Benign Conditions?

By C. Kramer, B. Zinman, R. Retnakaran. Annals of Internal Medicine, 2013

891 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/cf7317a02f6db1e3ad8b5f00aa384a82c279c363

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. I. Graham
2. T. Ivanova
3. F. B. Hu
4. M. Blüher

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. T. Ivanova
3. F. B. Hu
4. M. Blüher
5. Alberico L. Catapano

In Epidemiology

1. I. Graham
2. F. B. Hu
3. M. Blüher
4. Alberico L. Catapano

Citations in the corpus

• The Epidemiology of Obesity: A Big Picture (2015, background): “Recent studies have consistently shown that benign obesity appears to be a myth [106–108]; overweight clearly adds to the risk of heart disease and stroke beyond its implications for hypertension, dyslipidemia, and dysglycemia.”
• Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation (2017, background): “However, it is now clear from long-term follow-up studies that half or more of these individuals will develop obesity-related disease during their lifetime (43).”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “However, MHO individuals present a higher all-cause mortality compared with normal weight metabolically healthy individuals.(343,344) Long-term results from the Whitehall study support the notion that MHO is a transient phase(345) moving towards glucometabolic abnormalities rather than a specific ‘s”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “However, MHO individuals present a higher all-cause mortality compared with normal weight metabolically healthy individuals.(343,344) Long-term results from the Whitehall study support the notion that MHO is a transient phase(345) moving towards glucometabolic abnormalities rather than a specific ‘s”
• Metabolically Healthy Obesity (2020, background): “com/edrv cardiometabolic risk in people with obesity may be mediated by metabolic (elevated glucose, altered lipid profile) and cardiovascular (hypertension, circulating atherogenic factors) abnormalities, it has been postulated that people with MHO are protected against type 2 diabetes, ASCVD, and ”